Murine Tumor Model
Murine Tumor Model - Related Videos
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 8 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
07:59
Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
0 Views •
2026
A unique method to surgically resect oral squamous cell carcinoma tumors established in the oral cavity is shown here.
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
04:10
Surgical Cisterna Magna Injection: A Method for Administering Tumor Cells Directly into Central Nervous System of Murine Model
0 Views •
2023
In this video, we describe the procedure to deliver human-derived tumor cells into the cisterna magna of a mouse’s brain. The orthotopic mouse model can be used to study metastatic spread of cancer to the cranial meninges.
02:12
Evaluating the Anti-Tumor Efficacy of a Bacterial Immunomodulatory Protein in a Murine Model
0 Views •
2025
This video demonstrates a technique to assess the anti-tumor activity of Helicobacter pylori neutrophil-activating protein, or HP-NAP, in a mouse bladder cancer model. HP-NAP interacts with tumor-cell neutrophils to produce pro-inflammatory cytokines, inducing the differentiation of naïve T cells into type 1 T helper (Th1) and type 1 cytotoxic (Tc1) T cell phenotypes. The Th1 and Tc1 cells secrete interferon-gamma, inhibiting tumor angiogenesis and promoting cytotoxic T cell-mediated tumor...
FAQs
Model choice determines which biological interactions can be examined. Syngeneic tumors are studied in immunocompetent mice, allowing researchers to evaluate tumor behavior alongside host immune responses. Xenografts use human cancer cells and therefore support investigation of human tumor characteristics in mice. This distinction is especially important when interpreting studies of immune-system interactions, treatment response, or tumor progression.
Genetically engineered strains develop tumors through defined mutations, creating a system in which tumor formation is linked to specified molecular changes. This arrangement helps researchers examine how particular alterations influence development, progression, and signaling. It also provides a controlled context for studying tumor biology and for evaluating whether treatments affect cancers arising through defined genetic mechanisms.
Researchers monitor tumor growth, tissue pathology, molecular signaling, and host responses to build a broader picture of disease behavior. Growth measurements indicate how a tumor changes over time, while pathology examines tissue-level features. Molecular and host-response data add mechanistic context, helping connect treatment effects or progression with signaling changes and interactions between the tumor and the animal.
A study generally begins by generating or transplanting tumors in mice under controlled conditions. Researchers then follow tumor development and assess relevant tissue, molecular, and host-response changes. Experimental groups can receive anticancer drugs, immunotherapies, or combinations, after which investigators compare tumor growth and other measured outcomes. This workflow links an intervention with biological and treatment-related effects.
These models are useful when a study requires controlled testing of anticancer drugs, immunotherapies, or combination treatments before clinical studies. The selected system can be matched to the research question, such as immune interactions, tumor progression, or response to a defined mutation. Results may also reveal treatment resistance and potential toxicity, supporting decisions about further investigation.
By comparing tumor and host responses under different treatment conditions, investigators can identify whether a therapy limits tumor growth, produces evidence of resistance, or affects the animal in undesirable ways. Combining growth observations with pathology and molecular signaling data helps distinguish treatment outcomes from underlying biological mechanisms. This information contributes to preclinical assessment before clinical studies.